Literature DB >> 19734819

The Danish PEP registry: experience with the use of postexposure prophylaxis (PEP) following sexual exposure to HIV from 1998 to 2006.

Suzanne Lunding1, Terese L Katzenstein, Gitte Kronborg, Jens A Lindberg, Janne Jensen, Henrik I Nielsen, Court Pedersen, Louise B Jørgensen.   

Abstract

BACKGROUND: Studies indicate that antiretroviral postexposure prophylaxis (PEP) after sexual exposure to HIV reduce the risk of infection considerably. Since 1998 PEP after sexual HIV exposure within the preceding 24 hours, has been available in Denmark. PEP can only be prescribed at clinical centers with specialists experienced in HIV treatment. The objective of this study is to describe the use of PEP after sexual exposure from 1998 to 2006.
METHODS: The Danish PEP registry collects data from all cases of PEP use in Denmark after exposure to HIV through a structured questionnaire.
RESULTS: There were 374 cases of PEP use after sexual exposure. The incidence increased from 5 cases in 1997 to 87 in 2006. PEP was used by heterosexuals (40%) as well as men who have sex with men (57%). The HIV-status of the source was unknown in 41% of the cases of which 90% involved a source belonging to a high risk group, and 63% involved exposure by receptive anal intercourse. PEP was administered within 24 hours in 95% of the cases and the median time to initiation (N = 225) was 11.0 hours (range 0.5-60.0). PEP was completed by 65%.
CONCLUSIONS: This nationwide study showed a steady but moderate increase in the use of PEP after sexual HIV-exposure from 1998 to 2006. Time to initiation of PEP was low and the PEP prescription practice was targeted toward high risk exposures.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19734819     DOI: 10.1097/OLQ.0b013e3181b6f284

Source DB:  PubMed          Journal:  Sex Transm Dis        ISSN: 0148-5717            Impact factor:   2.830


  6 in total

1.  Non-occupational post-exposure prophylaxis for HIV: 10-year retrospective analysis in Seattle, Washington.

Authors:  Sarah J McDougal; Jeremiah Alexander; Shireesha Dhanireddy; Robert D Harrington; Joanne D Stekler
Journal:  PLoS One       Date:  2014-08-20       Impact factor: 3.240

2.  A randomized noninferiority trial of standard versus enhanced risk reduction and adherence counseling for individuals receiving post-exposure prophylaxis following sexual exposures to HIV.

Authors:  Michelle E Roland; Torsten B Neilands; Melissa R Krone; Thomas J Coates; Karena Franses; Margaret A Chesney; James S Kahn; Jeffrey N Martin
Journal:  Clin Infect Dis       Date:  2011-07-01       Impact factor: 9.079

Review 3.  Practical guidance for nonoccupational postexposure prophylaxis to prevent HIV infection: an editorial review.

Authors:  Sachin Jain; Kenneth H Mayer
Journal:  AIDS       Date:  2014-07-17       Impact factor: 4.177

4.  Pre-exposure and postexposure prophylaxes and the combination HIV prevention methods (The Combine! Study): protocol for a pragmatic clinical trial at public healthcare clinics in Brazil.

Authors:  Alexandre Grangeiro; Márcia Thereza Couto; Maria Fernanda Peres; Olinda Luiz; Eliana Miura Zucchi; Euclides Ayres de Castilho; Denize Lotufo Estevam; Rosa Alencar; Karina Wolffenbüttel; Maria Mercedes Escuder; Gabriela Calazans; Dulce Ferraz; Érico Arruda; Maria da Gloria Corrêa; Fabiana Rezende Amaral; Juliane Cardoso Villela Santos; Vivian Salles Alvarez; Tiago Kietzmann
Journal:  BMJ Open       Date:  2015-08-25       Impact factor: 2.692

5.  Suspected unexpected and other adverse reactions to antiretroviral drugs used as post-exposure prophylaxis of HIV infection - five-year experience from clinical practice.

Authors:  Justyna D Kowalska; Ewa Pietraszkiewicz; Ewa Firląg-Burkacka; Andrzej Horban
Journal:  Arch Med Sci       Date:  2016-05-05       Impact factor: 3.318

6.  Expert consensus statement on the science of HIV in the context of criminal law.

Authors:  Françoise Barré-Sinoussi; Salim S Abdool Karim; Jan Albert; Linda-Gail Bekker; Chris Beyrer; Pedro Cahn; Alexandra Calmy; Beatriz Grinsztejn; Andrew Grulich; Adeeba Kamarulzaman; Nagalingeswaran Kumarasamy; Mona R Loutfy; Kamal M El Filali; Souleymane Mboup; Julio Sg Montaner; Paula Munderi; Vadim Pokrovsky; Anne-Mieke Vandamme; Benjamin Young; Peter Godfrey-Faussett
Journal:  J Int AIDS Soc       Date:  2018-07       Impact factor: 5.396

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.